Mirador Capital Partners LP Has $863,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

Mirador Capital Partners LP raised its stake in Merck & Co., Inc. (NYSE:MRK) by 7.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,537 shares of the company’s stock after buying an additional 475 shares during the quarter. Mirador Capital Partners LP’s holdings in Merck & Co., Inc. were worth $863,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. Algert Global LLC acquired a new stake in Merck & Co., Inc. in the third quarter worth $454,000. Axxcess Wealth Management LLC raised its stake in Merck & Co., Inc. by 77.2% during the 3rd quarter. Axxcess Wealth Management LLC now owns 51,757 shares of the company’s stock worth $5,328,000 after buying an additional 22,546 shares during the period. AXQ Capital LP bought a new position in Merck & Co., Inc. during the third quarter worth about $1,421,000. Eubel Brady & Suttman Asset Management Inc. grew its stake in Merck & Co., Inc. by 2.3% in the third quarter. Eubel Brady & Suttman Asset Management Inc. now owns 4,652 shares of the company’s stock valued at $479,000 after acquiring an additional 105 shares during the period. Finally, Legacy Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 42.1% in the third quarter. Legacy Advisors LLC now owns 19,569 shares of the company’s stock worth $2,025,000 after acquiring an additional 5,795 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the topic of several recent analyst reports. Societe Generale cut Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a report on Monday, March 11th. Truist Financial upped their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Berenberg Bank upped their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Merck & Co., Inc. Stock Up 3.3 %

NYSE:MRK opened at $127.90 on Tuesday. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $134.63. The firm has a market capitalization of $323.95 billion, a price-to-earnings ratio of 142.11, a price-to-earnings-growth ratio of 2.39 and a beta of 0.38. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The stock’s 50 day moving average price is $129.32 and its two-hundred day moving average price is $124.39.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.40 earnings per share. Equities research analysts expect that Merck & Co., Inc. will post 8.62 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 annualized dividend and a yield of 2.41%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 342.22%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.